Premature Ejaculation (PE) Treatment Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Italy, UK, China, India - Size and Forecast 2024-2028

Published: Oct 2023

Pages: 167

SKU: IRTNTR70413

Snapshot

Premature Ejaculation (PE) Treatment Market 2024-2028

The Premature Ejaculation (PE) Treatment Market size is estimated to grow by USD 1,459.85 million at a CAGR of 8.78% between 2023 and 2028.

Key Findings:

Premature ejaculation treatment market remained historically at high levels from 2018 to 2023.
The market is segmented into route of administration, drug class, and geography.
Oral under the route of administration category generated the largest revenue in 2018.
Key regions boosting the market growth include North America, Europe, Asia, and Rest of World (ROW).

Premature ejaculation treatment market Share

For More Highlights About this Report, Download Free Sample in a Minute

Premature Ejaculation Treatment Market: Key Drivers, Trends and Challenges

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Premature Ejaculation Treatment Market Driver

The high efficacy of off-label premature ejaculation drugs is a major driver boosting the market growth. The global market for premature ejaculation treatment faces limitations in approved products, being predominantly driven by off-label drugs, generic versions, and over-the-counter formulations. The market's growth is propelled by the increasing demand for off-label drugs, notably SSRIs like paroxetine, fluoxetine, and sertraline, which were originally designed for mental health disorders but have shown effectiveness in delaying ejaculation. SSRIs, particularly paroxetine, exhibit a significant anti-ejaculatory effect within five to ten days.

PDE5 inhibitors, recognized as the primary treatment for erectile dysfunction, also demonstrate promise in treating premature ejaculation. Combining PDE5 inhibitors with SSRIs proves more effective than using SSRIs alone, as the improved erection inhibits ejaculation. Both drug classes are considered safe and effective for managing premature ejaculation, leading to widespread off-label use. The high efficacy of these drugs contributes to increased demand, propelling the growth of the global premature ejaculation treatment market during the forecast period.

Key Premature Ejaculation Treatment Market Trends

The advent of nanotechnology in premature ejaculation treatment drugs is a key trend shaping the market. Introduced in the 1980s, nanotechnology has revolutionized drug delivery system development for various diseases. Over the past decades, numerous nanotechnology-associated technologies have been clinically utilized, benefiting countless patients and promising a bright future for nanotechnology in medicine.

PDE-5 inhibitors like tadalafil, sildenafil, and vardenafil find off-label use in premature ejaculation treatment, but their oral administration poses challenges due to poor solubility and systemic side effects. Similarly, dapoxetine, an SSRI, faces low bioavailability orally. Nanotechnology offers new avenues for drug delivery, as demonstrated in a study by Han et al. Nanoparticles present a potential topical delivery route for erectogenic agents, improving safety profiles and minimizing side effects compared to oral administration or injections. In summary, nanotechnology opens new possibilities in drug delivery systems, contributing to market growth during the forecast period.

Major Premature Ejaculation Treatment Market Challenge

The availability of alternative treatment options for premature ejaculation is a key challenge hindering the market growth. While the market for premature ejaculation has limited approved products, the rising global cases have prompted alternative treatments' adoption, such as counseling, homeopathy, psychotherapy, yoga, and herbal therapy. Natural options like ginseng tea, raw almond milk, and Ayurvedic remedies are also considered.

Psychotherapy and behavioral therapies are common approaches, with psychotherapy being the first line for subjective premature ejaculation or cases with underlying psychological issues. However, it is time-consuming, costly, and less effective than pharmacotherapy. Psychosexual counseling addresses distress, while methods like meditation, hypnotherapy, and neuro-biofeedback enhance ejaculatory control. Behavioral therapies include techniques like precoital masturbation, stop-start and squeeze methods, condom use, and pelvic floor exercises. Breathing exercises, Kegel exercises, and Ayurvedic massage are recommended with minimal side effects compared to mainstream drugs. The growing popularity of these alternatives poses a threat to pharmaceutical therapies' growth in the market during the forecast period.

Premature Ejaculation Treatment Market Segmentations

Route of Administration Segment

The market share growth by the oral segment will be significant during the forecast period. The significant market share of the oral route segment can be attributed to the popularity and high preference for oral medication as the first line of treatment for premature ejaculation, owing to its ease of use and wide availability. These drugs are available in different forms, such as tablets, capsules, and liquids.

Get a glance at the market contribution of various segments Download the PDF Sample

The oral segment was the largest and was valued at USD 1,358.46 million in 2018. SSRIs were then used due to their sustained efficacy on ejaculatory latency and tolerable side effect profile. The mechanism for delayed ejaculation with SSRIs probably relates to the inhibition of multiple descending pathways associated with the ejaculatory reflex. This is supported by studies that show significant variations in cortical serotonergic function between patients with premature ejaculation in males. However, the non-availability of approved oral drugs to treat premature ejaculation in the US is attracting many large pharmaceutical companies to capitalize on the premature ejaculation (PE) treatment market by investing in R&D programs and developing new solutions. Such factors are expected to drive the growth of the oral segment in the market in focus during the forecast period.

Regional Analysis

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

North America dominates the premature ejaculation treatment market, primarily due to a significant rise in the number of premature ejaculation cases, owing to psychological strain and stress from an ever-changing lifestyle. Premature ejaculation is the most common sexual disorder in men younger than 40 years, with some degree at one time or another, which presents a significant market opportunity in the US alone. Several top vendors are headquartered in the region. They are either already offering premature ejaculation drugs or will be launching their products soon after approval from the US FDA.

In addition, the presence of off-label premature ejaculation solution providers such as Eli Lilly and Co. and Pfizer Inc. in the region has offered an alternate solution for the condition at a cheaper cost. An increase in the number of premature ejaculation cases will be addressed through a broad range of products in the pipeline. Increased R&D spending will further boost the growth of the regional premature ejaculation treatment market. Therefore, such factors are expected to drive the growth of the regional market during the forecast period.

Key Companies in Premature Ejaculation Treatment Market

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

A. Menarini Industrie Farmaceutiche Riunite Srl - The company offers premature ejaculation treatments such as Priligy and Spedra.

The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Premature Ejaculation Treatment Market Scope
Report Coverage	Details
Page number	167
Base year	2023
Historic period	2018 - 2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 8.78%
Market growth 2024-2028	USD 1,459.85 million
Market structure	Fragmented
YoY growth 2023-2024(%)	7.34
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 38%
Key countries	US, Italy, UK, China, and India
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	A. Menarini Industrie Farmaceutiche Riunite Srl, Absorption Pharmaceuticals LLC, Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Aytu BioPharma Inc., Bayer AG, Eli Lilly and Co., Futura Medical plc, GlaxoSmithKline Plc, Johnson and Johnson, LloydsPharmacy, Morari Inc., NeuroHealing Pharmaceuticals Inc., Niksan Pharmaceutical, Pfizer Inc., Plethora Solutions Ltd., Prinston Pharmaceutical Inc., Ralington Pharma LLP, Sunrise Remedies Pvt. Ltd., Tabuk Pharmaceuticals, Veru Inc., and VIVUS LLC
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download PDF Sample

What are the Key Data Covered in this Premature Ejaculation Treatment Market Research Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the market between 2024 and 2028
Precise estimation of the size of the market size and its contribution of the market in focus to the parent market
Accurate predictions about upcoming trends and changes in consumer behaviour
Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW)
Thorough analysis of the market’s competitive landscape and detailed information about companies
Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements.

Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Drug Class
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2023

3.4 Market outlook: Forecast for 2023-2028
- Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global premature ejaculation treatment market 2018 - 2022
- Exhibit 18: Historic Market Size – Data Table on global premature ejaculation treatment market 2018 - 2022 ($ million)

4.2 Route of Administration Segment Analysis 2018 - 2022
- Exhibit 19: Historic Market Size – Route of Administration Segment 2018 - 2022 ($ million)

4.3 Drug Class Segment Analysis 2018 - 2022
- Exhibit 20: Historic Market Size – Drug Class Segment 2018 - 2022 ($ million)

4.4 Geography Segment Analysis 2018 - 2022
- Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ million)

4.5 Country Segment Analysis 2018 - 2022
- Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2023 and 2028

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Route of Administration

6.1 Market segments
- Exhibit 30: Chart on Route of Administration - Market share 2023-2028 (%)
- Exhibit 31: Data Table on Route of Administration - Market share 2023-2028 (%)

6.2 Comparison by Route of Administration
- Exhibit 32: Chart on Comparison by Route of Administration
- Exhibit 33: Data Table on Comparison by Route of Administration

6.3 Oral - Market size and forecast 2023-2028
- Exhibit 34: Chart on Oral - Market size and forecast 2023-2028 ($ million)
- Exhibit 35: Data Table on Oral - Market size and forecast 2023-2028 ($ million)
- Exhibit 36: Chart on Oral - Year-over-year growth 2023-2028 (%)
- Exhibit 37: Data Table on Oral - Year-over-year growth 2023-2028 (%)

6.4 Topical - Market size and forecast 2023-2028
- Exhibit 38: Chart on Topical - Market size and forecast 2023-2028 ($ million)
- Exhibit 39: Data Table on Topical - Market size and forecast 2023-2028 ($ million)
- Exhibit 40: Chart on Topical - Year-over-year growth 2023-2028 (%)
- Exhibit 41: Data Table on Topical - Year-over-year growth 2023-2028 (%)

6.5 Market opportunity by Route of Administration
- Exhibit 42: Market opportunity by Route of Administration ($ million)
- Exhibit 43: Data Table on Market opportunity by Route of Administration ($ million)

7 Market Segmentation by Drug Class

7.1 Market segments
- Exhibit 44: Chart on Drug Class - Market share 2023-2028 (%)
- Exhibit 45: Data Table on Drug Class - Market share 2023-2028 (%)

7.2 Comparison by Drug Class
- Exhibit 46: Chart on Comparison by Drug Class
- Exhibit 47: Data Table on Comparison by Drug Class

7.3 SSRIs - Market size and forecast 2023-2028
- Exhibit 48: Chart on SSRIs - Market size and forecast 2023-2028 ($ million)
- Exhibit 49: Data Table on SSRIs - Market size and forecast 2023-2028 ($ million)
- Exhibit 50: Chart on SSRIs - Year-over-year growth 2023-2028 (%)
- Exhibit 51: Data Table on SSRIs - Year-over-year growth 2023-2028 (%)

7.4 PDE5 inhibitors - Market size and forecast 2023-2028
- Exhibit 52: Chart on PDE5 inhibitors - Market size and forecast 2023-2028 ($ million)
- Exhibit 53: Data Table on PDE5 inhibitors - Market size and forecast 2023-2028 ($ million)
- Exhibit 54: Chart on PDE5 inhibitors - Year-over-year growth 2023-2028 (%)
- Exhibit 55: Data Table on PDE5 inhibitors - Year-over-year growth 2023-2028 (%)

7.5 Amide anesthetics - Market size and forecast 2023-2028
- Exhibit 56: Chart on Amide anesthetics - Market size and forecast 2023-2028 ($ million)
- Exhibit 57: Data Table on Amide anesthetics - Market size and forecast 2023-2028 ($ million)
- Exhibit 58: Chart on Amide anesthetics - Year-over-year growth 2023-2028 (%)
- Exhibit 59: Data Table on Amide anesthetics - Year-over-year growth 2023-2028 (%)

7.6 Others - Market size and forecast 2023-2028
- Exhibit 60: Chart on Others - Market size and forecast 2023-2028 ($ million)
- Exhibit 61: Data Table on Others - Market size and forecast 2023-2028 ($ million)
- Exhibit 62: Chart on Others - Year-over-year growth 2023-2028 (%)
- Exhibit 63: Data Table on Others - Year-over-year growth 2023-2028 (%)

7.7 Market opportunity by Drug Class
- Exhibit 64: Market opportunity by Drug Class ($ million)
- Exhibit 65: Data Table on Market opportunity by Drug Class ($ million)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 67: Chart on Market share by geography 2023-2028 (%)
- Exhibit 68: Data Table on Market share by geography 2023-2028 (%)

9.2 Geographic comparison
- Exhibit 69: Chart on Geographic comparison
- Exhibit 70: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2023-2028
- Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ million)
- Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ million)
- Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
- Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)

9.4 Europe - Market size and forecast 2023-2028
- Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ million)
- Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
- Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
- Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)

9.5 Asia - Market size and forecast 2023-2028
- Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ million)
- Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
- Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
- Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)

9.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)

9.7 US - Market size and forecast 2023-2028
- Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ million)
- Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ million)
- Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
- Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)

9.8 Italy - Market size and forecast 2023-2028
- Exhibit 91: Chart on Italy - Market size and forecast 2023-2028 ($ million)
- Exhibit 92: Data Table on Italy - Market size and forecast 2023-2028 ($ million)
- Exhibit 93: Chart on Italy - Year-over-year growth 2023-2028 (%)
- Exhibit 94: Data Table on Italy - Year-over-year growth 2023-2028 (%)

9.9 China - Market size and forecast 2023-2028
- Exhibit 95: Chart on China - Market size and forecast 2023-2028 ($ million)
- Exhibit 96: Data Table on China - Market size and forecast 2023-2028 ($ million)
- Exhibit 97: Chart on China - Year-over-year growth 2023-2028 (%)
- Exhibit 98: Data Table on China - Year-over-year growth 2023-2028 (%)

9.10 UK - Market size and forecast 2023-2028
- Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ million)
- Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
- Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
- Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)

9.11 India - Market size and forecast 2023-2028
- Exhibit 103: Chart on India - Market size and forecast 2023-2028 ($ million)
- Exhibit 104: Data Table on India - Market size and forecast 2023-2028 ($ million)
- Exhibit 105: Chart on India - Year-over-year growth 2023-2028 (%)
- Exhibit 106: Data Table on India - Year-over-year growth 2023-2028 (%)

9.12 Market opportunity by geography
- Exhibit 107: Market opportunity by geography ($ million)
- Exhibit 108: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 109: Impact of drivers and challenges in 2023 and 2028

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 110: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 111: Overview on factors of disruption

11.4 Industry risks
- Exhibit 112: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 113: Vendors covered

12.2 Market positioning of vendors
- Exhibit 114: Matrix on vendor position and classification

12.3 A. Menarini Industrie Farmaceutiche Riunite Srl
- Exhibit 115: A. Menarini Industrie Farmaceutiche Riunite Srl - Overview
- Exhibit 116: A. Menarini Industrie Farmaceutiche Riunite Srl - Product / Service
- Exhibit 117: A. Menarini Industrie Farmaceutiche Riunite Srl - Key offerings

12.4 Absorption Pharmaceuticals LLC
- Exhibit 118: Absorption Pharmaceuticals LLC - Overview
- Exhibit 119: Absorption Pharmaceuticals LLC - Product / Service
- Exhibit 120: Absorption Pharmaceuticals LLC - Key offerings

12.5 Alembic Pharmaceuticals Ltd.
- Exhibit 121: Alembic Pharmaceuticals Ltd. - Overview
- Exhibit 122: Alembic Pharmaceuticals Ltd. - Product / Service
- Exhibit 123: Alembic Pharmaceuticals Ltd. - Key offerings

12.6 Amneal Pharmaceuticals Inc.
- Exhibit 124: Amneal Pharmaceuticals Inc. - Overview
- Exhibit 125: Amneal Pharmaceuticals Inc. - Business segments
- Exhibit 126: Amneal Pharmaceuticals Inc. - Key news
- Exhibit 127: Amneal Pharmaceuticals Inc. - Key offerings
- Exhibit 128: Amneal Pharmaceuticals Inc. - Segment focus

12.7 Aytu BioPharma Inc.
- Exhibit 129: Aytu BioPharma Inc. - Overview
- Exhibit 130: Aytu BioPharma Inc. - Product / Service
- Exhibit 131: Aytu BioPharma Inc. - Key offerings

12.8 Bayer AG
- Exhibit 132: Bayer AG - Overview
- Exhibit 133: Bayer AG - Business segments
- Exhibit 134: Bayer AG - Key news
- Exhibit 135: Bayer AG - Key offerings
- Exhibit 136: Bayer AG - Segment focus

12.9 Eli Lilly and Co.
- Exhibit 137: Eli Lilly and Co. - Overview
- Exhibit 138: Eli Lilly and Co. - Product / Service
- Exhibit 139: Eli Lilly and Co. - Key news
- Exhibit 140: Eli Lilly and Co. - Key offerings

12.10 Futura Medical plc
- Exhibit 141: Futura Medical plc - Overview
- Exhibit 142: Futura Medical plc - Product / Service
- Exhibit 143: Futura Medical plc - Key offerings

12.11 GlaxoSmithKline Plc
- Exhibit 144: GlaxoSmithKline Plc - Overview
- Exhibit 145: GlaxoSmithKline Plc - Business segments
- Exhibit 146: GlaxoSmithKline Plc - Key news
- Exhibit 147: GlaxoSmithKline Plc - Key offerings
- Exhibit 148: GlaxoSmithKline Plc - Segment focus

12.12 Johnson and Johnson
- Exhibit 149: Johnson and Johnson - Overview
- Exhibit 150: Johnson and Johnson - Business segments
- Exhibit 151: Johnson and Johnson - Key news
- Exhibit 152: Johnson and Johnson - Key offerings
- Exhibit 153: Johnson and Johnson - Segment focus

12.13 LloydsPharmacy
- Exhibit 154: LloydsPharmacy - Overview
- Exhibit 155: LloydsPharmacy - Product / Service
- Exhibit 156: LloydsPharmacy - Key offerings

12.14 NeuroHealing Pharmaceuticals Inc.
- Exhibit 157: NeuroHealing Pharmaceuticals Inc. - Overview
- Exhibit 158: NeuroHealing Pharmaceuticals Inc. - Product / Service
- Exhibit 159: NeuroHealing Pharmaceuticals Inc. - Key offerings

12.15 Pfizer Inc.
- Exhibit 160: Pfizer Inc. - Overview
- Exhibit 161: Pfizer Inc. - Product / Service
- Exhibit 162: Pfizer Inc. - Key news
- Exhibit 163: Pfizer Inc. - Key offerings

12.16 Plethora Solutions Ltd.
- Exhibit 164: Plethora Solutions Ltd. - Overview
- Exhibit 165: Plethora Solutions Ltd. - Product / Service
- Exhibit 166: Plethora Solutions Ltd. - Key offerings

12.17 Veru Inc.
- Exhibit 167: Veru Inc. - Overview
- Exhibit 168: Veru Inc. - Business segments
- Exhibit 169: Veru Inc. - Key offerings
- Exhibit 170: Veru Inc. - Segment focus

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 171: Inclusions checklist
- Exhibit 172: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 173: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 174: Research methodology
- Exhibit 175: Validation techniques employed for market sizing
- Exhibit 176: Information sources

13.5 List of abbreviations
- Exhibit 177: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

premature ejaculation treatment market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis